This week’s release of the Commonwealth Government COVID-19 Response Inquiry Report highlighted the National Clinical Evidence Taskforce as a successful and valued part of Australia's response to the pandemic, countering misinformation and providing a single source of evidence-based information to guide clinical decisions. The Taskforce was an initiative of the Australian Living Evidence Collaboration (ALEC), rapidly pivoting its resources in...

The National Clinical Evidence Taskforce welcomes recommendations from the Parliamentary Inquiry into Long COVID and Repeat COVID Infections to “[develop] evidence-based living guidelines for diagnosis and treatment incorporating...

The National COVID-19 Clinical Evidence Taskforce today published three recommendations on the use of sotrovimab for the treatment of COVID-19 in adults who do not require oxygen and...

Healthcare workers and trained first aid responders are being urged not to delay commencing cardiopulmonary resuscitation (CPR) because of the COVID-19 pandemic. The National COVID-19 Clinical Evidence Taskforce,...

The National COVID-19 Clinical Evidence Taskforce today gave a conditional recommendation for use of dexamethasone for the treatment of people with COVID-19 who are receiving oxygen or mechanical ventilation. The...

The National COVID-19 Clinical Evidence Taskforce (the Taskforce) has noted the media release of preliminary results from the dexamethasone arm of the RECOVERY (Randomised Evaluation of COVid-19 thERapY)...

The National COVID-19 Clinical Evidence Taskforce today gave a conditional recommendation for use of remdesivir in treatment of people with COVID-19. The Taskforce is comprised of 28 peak health...